Then They Lost Coverage." December 19, 2024
10.1002/alz.12482 Alzheimers Dement
Real evidence: A 12-week study: submaximal semaglutide improved metabolic markers but showed no change in the inflammatory markers IL-6, TNF-, or PAI-1 Semaglutide dose-response studies: effects require 0.2 mg/day, and even those effects are diminished when adjusted for weight change Meta-analyses showing anti-inflammatory effects correlate with improvements in insulin resistance and weight loss, not with microdosing voodoo magic
Wegovy may harm your unborn baby
The clinical rationale for obesity treatment extends beyond cosmetic benefit to meaningful cardiovascular risk reduction: Wegovy's label now includes cardiovascular risk reduction in overweight adults, fundamentally altering the value proposition for payers [1]
As mentioned above, GLP-1R signaling plays a natriuretic role to modulate Na + balance and prevents volume expansion (95)